Cochlear Limited, which creates implantable hearing devices, has taken a technological leap forward with a device that syncs up with various Apple products. The Nucleus 7 Sound Processor, which was ...

Cochlear reaffirmed guidance for FY 2025 underlying net profit between $410 million and $430 million, though it expects to achieve the lower end of this range. The revision is driven by weaker ...

LONE TREE, Colo., March 3, 2025 /PRNewswire/ — In celebration of World Hearing Day, Cochlear, the global leader in implantable hearing solutions, is proud to announce that it has been named the number ...

Morgan Stanley analyst Sean Laaman downgraded Cochlear Limited (CHEOF – Research Report) to a Sell today and set a price target of A$240.00. The company’s shares closed last Wednesday at $176.30.

Cochlear Limited, a medical device company specializing in implantable hearing solutions, is launching two new bone conduction sound processor devices for patients with high levels of hearing loss.

Cochlear Limited ((CHEOF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

Using visual support technology powered by TechSee, Cochlear has been able to bolster their customer experience by focusing on the needs of recipients through the use of Augmented Reality. NEW YORK, ...

Cochlear Limited (AU:COH) has released an update. Cochlear Limited has announced a new issuance of ordinary shares, with 94 securities set to be quoted on the Australian Securities Exchange on October ...

Cochlear Limited (AU:COH) has released an update. Cochlear Limited recently reported changes in the interests of its director, Diggory William Howitt, involving the acquisition of 11,000 shares and ...

Australians and New Zealanders with significant hearing loss are set to benefit from clearer, faster and more consistent access to cochlear implant ...

MONTPELLIER, France & SYDNEY--(BUSINESS WIRE)--Regulatory News: Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology, which specializes in the development of novel ...